Trade

with

Acorda Therapeutics Inc
(NASDAQ: ACOR)
AdChoices
31.77
-0.20
-0.63%
After Hours :
31.77
0.00
0.00%

Open

32.23

Previous Close

31.97

Volume (Avg)

596.72k (675.58k)

Day's Range

31.41-32.86

52Wk Range

27.51-39.95

Market Cap.

1.33B

Dividend Rate ( Yield )

-

Beta

1.37

Shares Outstanding

41.74M

P/E Ratio (EPS)

70.42 (0.45)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 336.43M

    • Net Income

    • 16.44M

    • Market Cap.

    • 1.33B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 5.37

    • PEG (Price/Earnings Growth) Ratio

    • 1.28

    • Beta

    • 1.37

    • Forward P/E

    • 25.00

    • Price/Sales

    • 3.78

    • Price/Book Value

    • 2.65

    • Price/Cash flow

    • 21.32

      • EBITDA

      • 38.03M

      • Return on Capital %

      • 2.51

      • Return on Equity %

      • 4.21

      • Return on Assets %

      • 2.51

      • Book Value/Share

      • 11.99

      • Shares Outstanding

      • 41.74M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Outperform
        • 1 Year Price Target

        • 45.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • 0.24

        • Cashflow Estimate

        • 0.55

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 11.60

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -89.40

          • 17.04

          • Net Income

            Q/Q (last year)

          • 19.80

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 47.72

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 80.11

            • 82.75

            • Pre-Tax Margin

            • 10.65

            • 39.38

            • Net Profit Margin

            • 5.37

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 79.80

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -18.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.57

              • 0.76

              • Current Ratio

              • 7.33

              • 2.92

              • Quick Ratio

              • 6.69

              • 2.35

              • Interest Coverage

              • 29.07

              • 38.02

              • Leverage Ratio

              • 1.89

              • 2.21

              • Book Value/Share

              • 11.99

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 68.97

                • 188.68

                • P/E Ratio 5-Year High

                • 90.48

                • 634.30

                • P/E Ratio 5-Year Low

                • 40.65

                • 124.82

                • Price/Sales Ratio

                • 3.70

                • 8.72

                • Price/Book Value

                • 2.60

                • 7.95

                • Price/Cash Flow Ratio

                • 21.32

                • 45.45

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 4.21

                        (3.30)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • 2.51

                        (2.50)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • 3.33

                        (1.90)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • 45.27k

                      • 117.08k

                      • Inventory Turnover

                      • 2.24

                      • 1.48

                      • Asset Turnover

                      • 0.47

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      30.36M
                      Operating Margin
                      9.03
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      21.32
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      58.07%

                      Mutual Fund Ownership

                      60.15%

                      Float

                      85.51%

                      5% / Insider Ownership

                      2.24%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        3,478,900

                      • 0.00

                      • 8.33

                      • Eagle Small Cap Growth Fund

                      •  

                        1,178,264

                      • 0.00

                      • 2.82

                      • ClearBridge Small Cap Growth Fund

                      •  

                        901,414

                      • 0.00

                      • 2.20

                      • iShares Core S&P Small-Cap (AU)

                      •  

                        831,537

                      • 0.37

                      • 1.87

                      • Vanguard Small Cap Index

                      •  

                        725,101

                      • -0.12

                      • 1.74

                      • Vanguard Total Stock Mkt Idx

                      •  

                        688,889

                      • 0.18

                      • 1.65

                      • iShares Russell 2000 (AU)

                      •  

                        651,169

                      • -1.01

                      • 1.46

                      • Fidelity® Independence Fund

                      •  

                        650,000

                      • 0.00

                      • 1.56

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        613,487

                      • 0.00

                      • 1.47

                      • SPDR® S&P Biotech ETF

                      •  

                        559,894

                      • 0.60

                      • 1.26

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        6,297,690

                      • +73.85%

                      • 15.09

                      • Vanguard Group, Inc.

                      •  

                        2,781,919

                      • +0.32%

                      • 6.78

                      • BlackRock Fund Advisors

                      •  

                        2,652,333

                      • -5.10%

                      • 6.46

                      • Eagle Asset Management, Inc.

                      •  

                        2,472,471

                      • +3.39%

                      • 5.92

                      • Oracle Investment Management Inc

                      •  

                        1,931,414

                      • -1.28%

                      • 4.70

                      • UBS Global Asset Mgmt Americas Inc

                      •  

                        1,586,196

                      • +12.67%

                      • 3.86

                      • State Street Corp

                      •  

                        1,314,725

                      • -5.39%

                      • 3.20

                      • Wellington Management Company, LLP

                      •  

                        1,229,991

                      • +4.43%

                      • 3.00

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      Acorda Therapeutics, Inc. was incorporated on March 17, 1995 as a Delaware corporation. It is a biopharmaceutical company, engaged in the identification, development and commercialization of novel therapies that improve neurological ...morefunction in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The first product for which it completed clinical development, Ampyra (dalfampridine) Extended Release Tablets, 10mg was approved by the U.S. Food and Drug Administration, or FDA, in January 2010 as a treatment to improve walking in patients with MS. Ampyra is marketed as Fampyra outside the U.S. by Biogen Idec International GmbH, or Biogen Idec. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a shor...moret-acting drug approved by the FDA for the management of spasticity. The Company is developing a pipeline of novel neurological therapies. It is studying dalfampridine to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, it is developing its clinical stage compound AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and SCI. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in SCI. It also has trademark registrations for “Fampyra” and “Kampyra” and pending trademark applications therefor, in numerous foreign jurisdictions. It also owns the rights to the registered marks "Zanaflex" and "Zanaflex Capsules" and “Qutenza” in the U.S. In addition, its trademark portfolio includes several trademark registrations and pending trademark applications for potential product names and for disease awareness activities. The Company is subject to periodic unannounced inspections by the FDA and other regulatory bodies related to the other regulatory requirements that apply to marketed drugs manufactured or distributed by the Company.lessless

                      Key People

                      Ron Cohen,M.D.

                      CEO/Chairman of the Board/Director/Founder/President

                      Michael W. Rogers

                      CFO/Chief Accounting Officer

                      Lauren M. Sabella

                      Executive VP, Divisional

                      Mr. Lorin Jeffry (Jeff) Randall

                      Director

                      Steven M. Rauscher

                      Director

                      • Acorda Therapeutics Inc

                      • 420 Saw Mill River Road

                      • Ardsley, NY 10502

                      • USA.Map

                      • Phone: +1 914 347-4300

                      • Fax: +1 914 347-4560

                      • acorda.com

                      Incorporated

                      1995

                      Employees

                      421

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: